Review Article
EDTA: Ethylene Diamine Tetra Acetic Acid – A Review
Eleonore Kaethe Blaurock-Busch*
Micro Trace Minerals Clinical Laboratory, Germany
- *Corresponding Author:
- Blaurock-Busch EK
Research and quality control director, Micro Trace Minerals Clinical Laboratory
Röhrenstr 20, 91217, Hersbruck/Germany
Tel: +49-91-51- 816535
E-mail: ebb@microtrace.de
Received date: July 29, 2016; Accepted date: September 07, 2016; Published date: September 14, 2016
Citation: Blaurock-Busch EK (2016) EDTA: Ethylene Diamine Tetra Acetic Acid – A Review. Occup Med Health Aff 4:245. doi: 10.4172/2329-6879.1000245
Copyright: © 2016 Blaurock-Busch EK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Chelation therapists around the world incorporate chelation therapies into their daily medical practice, frequently using EDTA (ethylene diamine tetra acetic acid) compounds, unaware of the chemical difference of the various EDTA chelating agents. With this information, we aim to clarify the different mode of action of the EDTAs, including their appropriate medical use. In the USA, medical practitioners promote EDTA chelation, often as an alternative to conventional treatments for a variety of chronic diseases, including vascular problems. German nonmedical professionals use the ‘CaEDTA push’ as promoted by US web pages, although this is against standard protocol. CaEDTA has been FDA- approved for lead intoxication only, and Na2EDTA has not been approved for the treatment of cardiovascular disease. These facts are often overlooked. Misunderstandings increase the risk of iatrogenic accidents. This information aims to prevent this.
